(Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, ...

Gig roles are emerging in India's corporate sector, with IT, pharmaceuticals, and energy firms hiring senior executives on ...

Good morning, and welcome to the Altamira Therapeutics First Half 2024 and Business Update Conference Call. On today's call are Thomas Meyer, Altamira's Founder, Chairman and Chief Executive Officer; ...

The NJBIZ Empowering Women program celebrates businesses that have implemented initiatives and policies aimed at fostering a more inclusive and supportive environment for women, providing them with ...

Silexion Therapeutics Corp. (NASDAQ:SLXN) stock is up more than 21.72% in pre-market trading Tuesday after the company ...

Altamira’s Senior Management will hold an investor call today, Tuesday, September 24, 2024, at 8:30 a.m. EDT its business update and first half 2024 results. Founder, Chairman, and CEO Thomas Meyer ...

Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced significant new findings from ...

New research from the University of Dundee shows potential breakthrough for hard to treat cancers. Experts from the ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA ...

Small-molecule drug (ACBI3) could potentially lead to new therapies independent of KRAS mutation type, improving outcomes for ...

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

Molecule sends 13 of the 17 most common forms of this cancer-related protein to the cell’s garbage-disposal system ...